Catalog No.
Product Name
Application
Product Information
Citations
-
TrxR/EGFR Inhibitor
TrxR/EGFR-IN-1 is a potent inhibitor targeting both Thioredoxin Reductase (TrxR) and Epidermal Growth Factor Receptor (EGFR). This compound demonstrates significant anti-proliferative effects against Gefitinib-sensitive and resistant lung cancer cells, facilitating apoptosis and tumor cell death. TrxR/EGFR-IN-1 promotes GPX4 protein degradation via autophagolysosomal and proteasomal pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it a valuable tool for studying mechanisms underlying Gefitinib-resistant lung cancer. -
Ferroptosis Inducer
Chlorido[N,N'-disalicylidene-1,2-phenylenediamine]iron(III) acts as a ferroptosis inducer by generating lipid-based reactive oxygen species (ROS). This compound is instrumental for research exploring the mechanisms of ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation. It is valuable for studies investigating cancer biology, neurodegenerative diseases, and other conditions where ferroptosis plays a critical role. -
Ferroptosis Inhibitor
Ferroptosis-IN-4 is a potent ferroptosis inhibitor, exhibiting an EC50 value of 20 μM. This compound demonstrates minimal cytotoxicity, highlighting its safety for biological applications. Ferroptosis-IN-4 provides a protective effect in models of glycerol-induced renal acute kidney injury (RM-AKI), effectively alleviating kidney dysfunction. Its ability to modulate ferroptosis makes it a valuable tool for research in cellular stress responses and kidney-related disorders. -
Ferroptosis Inducers
Ferroptocide is a potent inducer of ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation. It effectively induces oxidative stress, resulting in G2/M cell cycle arrest and apoptosis in LNCaP cells, and significantly reduces cell viability in both LNCaP and TRAMP-C1 prostate cancer cell lines. Ferroptocide serves as a valuable tool for investigating mitochondrial autophagy and evaluating its potential to trigger immunogenic cell death (ICD) in prostate cancer research. -
Ferroptosis Inducer
Chaetoglobosin E is a potent ferroptosis inducer that targets and downregulates GPX4 expression in human tumor cell lines. It exhibits significant cytotoxic effects, with IC50 values of 9.14 μM against MDA-MB231 cells and 7.47 μM against A549 cells. The compound elevates intracellular Fe2+ levels and increases the lipid peroxidation marker malondialdehyde (MDA), resulting in mitochondrial alterations and the induction of ferroptosis. Chaetoglobosin E serves as a valuable tool for cancer research and the study of ferroptosis mechanisms. -
Ferroptosis Inducer
Fluorescein-diisobutyrate-6-amide is a potent ferroptosis inducer targeting the cell death pathway associated with iron metabolism. This compound primarily promotes oxidative stress, leading to lipid peroxidation and subsequent cell apoptosis. Fluorescein-diisobutyrate-6-amide is valuable for research applications in cancer biology, particularly in understanding ferroptosis mechanisms and exploring novel therapeutic strategies against various malignancies. -
Ferroptosis Inducer
Talaroconvolutin A is a potent ferroptosis inducer that primarily acts by elevating reactive oxygen species (ROS) levels while bypassing the GPX4 pathway. This compound downregulates the expression of solute carrier family 7 member 11 (SLC7A11) and enhances arachidonic acid lipoxygenase 3 (ALOXE3) levels. Talaroconvolutin A demonstrates significant cytotoxicity in colorectal cancer cells (HCT116) and bladder cancer cells (SW480), with IC50 values of 1.22 μM and 1.4 μM, respectively. This reagent is valuable for researching ferroptosis mechanisms and therapeutic strategies in colorectal and bladder cancers. -
Ferroptosis Inhibitor
5-Hydroxy-6,7-dimethoxyflavone is a potent inhibitor of ferroptosis, acting primarily to mitigate H1N1 virus-induced cell death. This compound enhances the expression of SLC7A11 and GPX4, thereby providing protective effects against ferroptosis. Additionally, it reduces inflammatory responses and apoptosis by inhibiting the activation of NF-κB and p38 MAPK signaling pathways. 5-Hydroxy-6,7-dimethoxyflavone is valuable for research related to H1N1 influenza virus infection and ferroptosis regulation. -
Ferroptosis inhibitor
3-Hydroxyindole is a hydroxyindole derivative known for its potent antioxidant activity. It exhibits inhibitory effects against DPPH and crocin, making it a valuable tool in studies of oxidative stress. Additionally, 3-hydroxyindole is recognized for its role as a ferroptosis inhibitor, facilitating research into this regulated form of cell death and its implications in various diseases. -
Ferroptosis Inducer
(1R,3R)-Ferroptosis inducer-1 is a selective ferroptosis inducer that demonstrates significant antitumor activity. This compound promotes ferroptotic cell death, a form of regulated necrosis characterized by lipid peroxidation, making it valuable for research in cancer biology. It has potential applications in the study of therapeutic strategies targeting ferroptosis in various cancer types. -
PPARγ Agonist
Rosiglitazone potassium is a selective PPARγ agonist with an EC50 of 60 nM and a Kd of 40 nM. This compound also acts as a TRPC5 activator (EC50: 30 μM) while inhibiting TRPM3. It is utilized in research investigating obesity, diabetes, cellular senescence, and ovarian cancer. -
PPARγ Agonist
Pioglitazone potassium is a selective agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), demonstrating high-affinity binding to the PPARγ ligand-binding domain with EC50 values of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. This compound is commonly utilized in diabetes research to explore its effects on insulin sensitivity and glucose metabolism. Its action on PPARγ makes it a valuable tool for studying metabolic disorders and related therapeutic interventions. -
Ferroptosis Inducer
NA-Ir is a potent ferroptosis inducer that targets mitochondrial DNA (mtDNA) and activates the cGAS-STING signaling pathway, promoting ferritinophagy. It generates reactive oxygen species (ROS) through photodynamic therapy (PDT) while depleting glutathione (GSH) and downregulating glutathione peroxidase 4 (GPX4), leading to lipid peroxidation and the initiation of ferroptosis. NA-Ir demonstrates increased anticancer efficacy when exposed to light, selectively impairing cancer cells characterized by elevated levels of hydrogen sulfide (H2S). -
Ferroptosis Makers
PRDX3(103-112), human is a critical marker for ferroptosis, a form of regulated cell death influenced by oxidative stress. This peptide is generated from PRDX3, which undergoes hyperoxidation in response to mitochondrial lipid peroxides. Following hyperoxidation, PRDX3 plays a role in the inhibition of cystine uptake, contributing to the regulation of glutathione and cellular redox balance. Applications include studying the mechanisms of ferroptosis in various disease models and evaluating therapeutic interventions targeting oxidative stress. -
Ferroptosis Inducer
Ferroptosis inducer-8 is a potent ferroptosis inducer that selectively targets other cell death pathways. It functions by modulating the expression of ACSL4, GPX4, and FTH1, thereby disrupting iron homeostasis and impairing the GSH/GPX4 antioxidant defense system. This mechanism facilitates lipid peroxidation and promotes reactive oxygen species (ROS) production. Ferroptosis inducer-8 has demonstrated efficacy in inhibiting tumor growth, making it a valuable tool for research in triple-negative breast cancer (TNBC) and other malignancies. -
Ferroptosis Inhibitor
Ferroptosis-IN-5 is a potent ferroptosis inhibitor that functions by chelating iron and scavenging reactive oxygen species (ROS). This compound effectively mitigates ferroptotic cell death, making it valuable for research in cancer biology and neurodegeneration. Applications include investigating the mechanisms of ferroptosis and evaluating potential therapeutic interventions in various diseases associated with oxidative stress. -
Ferroptosis Inducer
BG11 is a potent ferroptosis inducer that promotes the accumulation of Fe2+ ions and intracellular lipid peroxides, leading to ferroptotic cell death. It modulates the expression of apoptotic regulators such as Bax and Bcl-2, facilitating apoptosis in MDA-MB-231 breast cancer cells. Furthermore, BG11 causes G0/G1 and S phase cell cycle arrest, significantly inhibiting the proliferation, migration, and invasion of triple-negative breast cancer (TNBC) cells, with IC50 values of 0.49 μM for MDA-MB-231 and 0.52 μM for BT549. In preclinical mouse models, BG11 demonstrates notable antitumor efficacy. -
Ferroptosis Inhibitor
Ferfluor-1 is a potent ferroptosis inhibitor, demonstrating EC50 values of 57 nM in HT108 cells, 75 nM in OS-RC-2 cells, and 2.3 nM in SH-SY5Y neuroblastoma cells. This ratiometric photoluminescent probe is capable of crossing the blood-brain barrier, making it an effective tool for monitoring ferroptotic changes in cellular environments. Ferfluor-1 shows promise in research applications related to neurodegenerative diseases, such as stroke and Parkinson's disease, by mitigating the effects of ferroptosis in in vivo models. -
Ferroptosis Inducer
Anti-TNBC agent-13 is a ferroptosis inducer designed to target and inhibit GPX4 activity. By promoting the accumulation of lipid peroxides, it triggers cell death specifically in triple-negative breast cancer (TNBC) cells. This compound serves as a valuable research tool for studying ferroptosis and its therapeutic potential in TNBC. -
Ferroptosis Inducer
Ferroptosis inducer-13 is a 5′-prenylated chalcone derivative that targets and induces ferroptosis in human non-small cell lung cancer (NSCLC) cells by modulating the Nrf2/xCT/GPX4 pathway. This compound demonstrates significant anti-proliferative effects in vitro and effectively inhibits tumor growth in NSCLC mouse models. Ferroptosis inducer-13 serves as a valuable tool for research focused on the mechanisms and treatment of NSCLC. -
Ferroptosis Inducer
Cetzole is a potent ferroptosis inducer that promotes cell death through the accumulation of reactive oxygen species (ROS). With CC50 values ranging from 2.56 μM in NCI-H522 cells to 14.9 μM in NARF2 cells, Cetzole demonstrates significant cytotoxicity across various cancer cell lines. This compound is valuable for research focused on cancer biology and the mechanisms of ferroptosis. -
Ferroptosis Inhibitor
Ferroptosis-IN-15 is a potent ferroptosis inhibitor, exhibiting EC50 values of 0.76 μM in A375 cells and 0.67 μM in 786-O cells. This compound functions as a potential iron chelator and radical trapping antioxidant, making it a valuable tool for studying the mechanisms of ferroptosis. Its ability to modulate ferroptotic cell death contributes to research in cancer biology and neurodegenerative disorders. -
Ferroptosis Inducer
Ferroptosis Inducer-5 (compound 20a) is a potent inducer of ferroptosis, a form of regulated cell death characterized by lipid peroxidation and iron dependency. It exhibits significant biological activity in promoting ferroptotic cell death in various cancer cell lines. This reagent is valuable for research applications exploring the mechanisms of ferroptosis and its therapeutic implications in cancer treatment. -
Ferroptosis Inhibitor
Ferroptosis-IN-18 is a potent ferroptosis inhibitor that exhibits significant anti-ferroptotic and antioxidant properties. This compound is particularly relevant in research focused on intracerebral hemorrhage (ICH), providing valuable insights into the mechanisms of ferroptosis and potential therapeutic approaches. Its ability to modulate ferroptosis-related pathways makes it a valuable tool in the understanding of oxidative stress-related conditions. -
Ferroptosis inhibitor
Myosin-IN-3 is a pyrimidine ketone derivative that functions as a ferroptosis inhibitor. Demonstrating potent anti-ferroptotic activity with an IC50 of 3.11 μM, it also effectively inhibits myosin activity (IC50 = 3.09 μM) and exhibits antioxidant properties, as evidenced by DPPH (EC50 = 23.17 μM) and MDA (EC50 = 55.34 μM) assays. Myosin-IN-3 is applicable in research related to cardiovascular diseases, including hypertrophic cardiomyopathy. -
Ferroptosis Inducer
Ferroptosis inducer-4 is a potent ferroptosis inducer that introduces terminal double bonds at the sn-2 position of phospholipids. This compound exhibits significant cytotoxicity in HT-1080 cells, with an IC50 of 18 μM, through the generation of lipid peroxides leading to oxidative damage of the cell membrane. Ferroptosis inducer-4 is valuable for research involving the regulation and mechanisms of ferroptosis in various biological contexts. -
Apoptosis/Ferroptosis Inducer
Anticancer agent 199 is an apoptosis and ferroptosis inducer targeting multiple signaling pathways in triple negative breast cancer (TNBC) cells. It promotes cell death through the mitochondrial pathway by inhibiting EGFR, AKT, and MAPK signaling, while simultaneously down-regulating LCN2 to induce ferroptosis. This compound effectively reduces TNBC cell viability and migration, and induces S phase cell cycle arrest, making it a valuable tool for research on cancer therapeutics. Anticancer agent 199 is a derivative of the cyclin-dependent kinase inhibitor Rocovitine. -
Ferroptosis Inducer
Anticancer agent 194 is a potent ferroptosis inducer that also promotes autophagy. This compound selectively arrests the colon cancer cell cycle at the G2/M phase while not triggering apoptotic pathways. Anticancer agent 194 exerts its biological effects through the significant accumulation of reactive oxygen species (ROS), making it a valuable tool for research on ferroptosis and cancer therapy strategies. -
Selective PPARγ Agonist
Pioglitazone-d4 is a deuterium-labeled derivative of Pioglitazone, a selective agonist of the peroxisome proliferator-activated receptor gamma (PPARγ). This compound demonstrates high affinity for the PPARγ ligand-binding domain, with EC50 values of 0.93 μM for human and 0.99 μM for mouse PPARγ. Pioglitazone-d4 is utilized in metabolic research to study insulin sensitivity, adipogenesis, and the mechanisms underlying type 2 diabetes mellitus. -
Ferroptosis Inhibitor
Ferroptosis-IN-6 is a potent ferroptosis inhibitor with an EC50 of 25.5 nM. This compound effectively inhibits RSL3-induced cell death both in vitro and in vivo, making it a valuable tool for studying ferroptosis mechanisms. Its applications include investigating cell death pathways and potential therapeutic strategies in cancer and neurodegenerative diseases. -
Ferroptosis Inhibitor
CuATSP is a potent inhibitor of ferroptotic cell death, demonstrating approximately 20-fold greater efficacy compared to its predecessor, CuATSM. This compound has significant implications for research focused on cell death mechanisms and oxidative stress-related diseases. It is valuable for studying the pathways involved in ferroptosis and its potential therapeutic applications in various conditions, including neurodegenerative disorders and cancer. -
Ferroptosis Regulator
2-Acetamidophenol, an ortho-regioisomer of Paracetamol, serves as a ferroptosis regulator, primarily influencing glutathione metabolic pathways. This compound exhibits anti-atherosclerotic properties, effectively reducing total cholesterol and triglyceride levels in zebrafish hyperlipidemia models with IC50 values of 30 μM and 40 μM, respectively. Additionally, 2-Acetamidophenol promotes the expression of genes associated with glutathione synthesis and iron ion transport, mitigates intracellular reactive oxygen species and ferrous ion accumulation, and enhances glutathione peroxidase GPX4 activity, consequently inhibiting macrophage phagocytosis of oxidized low-density lipoprotein and foam cell development. -
Ferroptosis Inducer
Ferroptosis inducer-2 is a potent inducer of heme oxygenase-1 (HO-1) that facilitates the process of ferroptosis. It demonstrates significant anticancer activity against triple-negative breast cancer (TNBC) cells by promoting iron-dependent cell death. This compound is valuable for research focused on exploring the mechanisms of ferroptosis and developing novel therapeutic strategies for cancer treatment. -
15-Lipoxygenase Inhibitor
Utreloxastat (PTC857) is a selective inhibitor of 15-lipoxygenase, capable of crossing the blood-brain barrier. This compound demonstrates a significant ability to reduce oxidative stress, inhibit the depletion of reduced glutathione, and prevent ferroptosis. Utreloxastat is particularly relevant in the research of neurodegenerative diseases associated with elevated oxidative stress and mitochondrial dysfunction, including conditions such as amyotrophic lateral sclerosis. -
Ferroptosis Inducer
Ferroptosis inducer-1 (BX-3a) is a potent inducer of ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation. This compound exhibits antitumor activity and serves as a valuable tool for investigating ferroptosis pathways in cancer research. Ferroptosis inducer-1 features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating advanced chemical biology applications. -
Ferroptosis/NETosis Inhibitor
IM-93 is a potent inhibitor of ferroptosis and NETosis, with an IC50 of 0.45 µM for the inhibition of cell death. This compound serves as a valuable tool for researchers investigating the mechanisms of ferroptosis and NETosis in various biological contexts. Its ability to modulate these cell death pathways can aid in the exploration of therapeutic strategies for diseases associated with oxidative stress and inflammation. -
Ferroptosis Inhibitor
Ferroptosis-IN-19 is a potent ferroptosis inhibitor exhibiting an IC50 value of 0.097 μM. This compound demonstrates high metabolic stability and favorable predictions for blood-brain barrier permeation. Ferroptosis-IN-19 has been shown to provide neuroprotective effects in vivo against ischemic brain injury in murine models, making it a valuable tool for exploring ferroptosis in neurological research. -
Ferroptosis Inhibitor
Ferroptosis-IN-8 is a potent ferroptosis inhibitor with an EC50 of 40.49 nM. This compound effectively lowers lipid reactive oxygen species (ROS) levels in cellular systems. By acting as an antioxidant that captures lipid radicals, Ferroptosis-IN-8 mitigates the accumulation of detrimental lipid peroxides, thereby inhibiting the ferroptotic process. This reagent is valuable for research in cell death mechanisms and oxidative stress. -
Ferroptosis Inhibitor
Ferroptosis-IN-21 is a selective ferroptosis inhibitor that mitigates renal ischemia/reperfusion (I/R) injury by suppressing ferroptosis and effectively scavenging peroxyl radicals. Demonstrating nanomolar potency, it exhibits significant anti-ferroptotic activity in renal tubular epithelial cells, leading to a marked reduction in lipid reactive oxygen species (ROS) and lipid peroxidation biomarkers such as 4-hydroxynonenal. In preclinical studies, Ferroptosis-IN-21 has shown to alleviate histological damage and functional impairment in mice models of renal I/R injury, making it a valuable reagent for research in ferroptosis-targeted therapeutic development. -
Ferroptosis Inhibitor
Ferroptosis-IN-22 is a selective ferroptosis inhibitor that targets and disrupts the interaction between NCOA4 and ferritin, demonstrating an EC50 of 520 nM and a Kd of 0.78 μM. This compound exhibits potent inhibitory activity against ferroptosis induced by agents such as RSL3, Erastin, ML210, and FIN56, while sparing necrosis and apoptosis pathways. Ferroptosis-IN-22 has shown efficacy in ameliorating acute liver injury induced by Concanavalin A, making it a valuable tool for research in ferroptosis-related diseases. -
Ferroptosis Inducer
BCP-T.A is a tunable heterocyclic electrophile that functions as a potent inducer of ferroptosis by targeting glutathione peroxidase 4 (GPX4). This compound possesses an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with azide-containing molecules. BCP-T.A is valuable for studies on ferroptosis mechanisms and the development of therapeutic strategies targeting this regulated form of cell death. -
Ferroptosis Inducer
FINO2 is a potent inducer of ferroptosis, primarily acting through the inhibition of GPX4 activity. This reagent is a stable oxidant that facilitates the oxidation of ferrous iron and is effective across a range of pH levels. Its mechanism drives extensive lipid peroxidation, making it a valuable tool for research into ferroptosis and related cellular death pathways. -
xc(-) Cystine/Glutamate Transporter System Inhibitor, ferroptosis inducer
Erastin2 is a selective inhibitor of the xc(-) cystine/glutamate transporter, functioning as a potent inducer of ferroptosis. This compound disrupts intracellular cystine availability, leading to increased oxidative stress and subsequent cell death. Erastin2 is valuable for research applications targeting ferroptosis in cancer biology and neurodegenerative diseases, providing insights into therapeutic strategies that exploit this regulated cell death pathway. -
Ferroptosis inhibitor
Trans-3-Indoleacrylic acid is a ferroptosis inhibitor that acts through modulation of the AHR-ALDH1A3-FSP1-CoQ10 axis. It has been shown to promote tumor development by inhibiting RSL3-induced ferroptosis, thereby contributing to the progression of colorectal carcinogenesis. This compound serves as a valuable tool for research into ferroptosis mechanisms and cancer biology. -
HMG-CoA Reductase Inhibitor
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect. -
Ferroptosis Inducer
N6F11 is a selective ferroptosis inducer that targets TRIM25 to promote the degradation of GPX4 in cancer cells while preserving immune cell functionality. This compound triggers HMGB1-dependent antitumor immunity, activating CD8+ T cells and enhancing the immune response against tumors. N6F11 is suitable for research applications focused on cancer therapy and the mechanisms underlying ferroptosis. -
Ferroptosis Inhibitor
84-B10 is a potent ferroptosis inhibitor derived from 3-phenylglutaric acid. It effectively inhibits cisplatin-induced tubular ferroptosis, thereby mitigating mitochondrial damage and oxidative stress associated with cisplatin treatment. Consequently, 84-B10 demonstrates protective effects against cisplatin-induced acute kidney injury (AKI), making it a valuable reagent for research on drug-induced nephrotoxicity and ferroptosis-related mechanisms. -
Endogenous Metabolite
L-Cystine dihydrochloride is the dihydrochloride salt of the endogenous metabolite L-Cystine, functioning primarily as an activator of the Nrf2 transcription factor. This compound enhances Nrf2 protein expression, leading to a reduction in reactive oxygen species (ROS) generation and protection against apoptosis induced by oxidants or Doxorubicin. Additionally, L-Cystine dihydrochloride, in combination with L-theanine, promotes the production of antigen-specific IgG and modulates T helper 2 (Th2) responses by elevating glutathione (GSH) levels in murine models. It holds potential for investigating conditions such as cystinuria and the formation of kidney stones. -
ZIKV And EBOV Inhibitor, Histone H3 Acetylation Inductor, Ferroptosis Inductor
Cephaeline is a phenolic alkaloid derived from the roots of Cephaelis ipecacuanha, functioning as a potent inhibitor of Zika virus (ZIKV) and Ebola virus (EBOV) infections. It induces histone H3 acetylation, playing a role in epigenetic regulation, and has been shown to induce ferroptosis in mucoepidermoid carcinoma cancer stem cells by inhibiting NRF2. This makes Cephaeline a valuable reagent for researchers studying antiviral mechanisms and ferroptosis in cancer therapy. -
Ferroptosis Inhibitor
Liproxstatin-1 hydrochloride is a potent inhibitor of ferroptosis, a regulated form of cell death characterized by lipid peroxidation. It effectively prevents ferroptotic cell death with an IC50 value of 22 nM. This compound is valuable for research applications focused on oxidative stress, neurodegenerative diseases, and cancer, where modulating ferroptosis may provide therapeutic insights.
